Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;185(3):555-562.
doi: 10.1111/bjd.19897. Epub 2021 Jun 8.

Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan shows a discrepancy in patient-reported outcome measures

L E M de Wijs  1 , R F T Fujimoto  2 , E R Andrinopoulou  3 , T Nijsten  1 , D Hijnen  1 , Y Kataoka  2
Affiliations

Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan shows a discrepancy in patient-reported outcome measures

L E M de Wijs et al. Br J Dermatol. 2021 Sep.

Abstract

Background: Dupilumab was equally effective among all racial subgroups in clinical trials, but a direct comparison in daily practice is lacking.

Objectives: To investigate the effectiveness of dupilumab in patients with atopic dermatitis (AD) in the Netherlands and Japan over 80 weeks of treatment.

Methods: A longitudinal comparative cohort study was conducted in patients with AD who were treated with dupilumab in daily practice. We used linear mixed-effects models to determine changes over time.

Results: We found statistically significant differences in sex, disease onset, body mass index and therapeutic history between Dutch (n = 208) and Japanese (n = 153) patients. The baseline Eczema Area and Severity Index (EASI) score was higher in Japanese patients (23·8 vs. 14·8), while baseline Patient-Reported Outcome Measures (PROMs) were higher in Dutch patients. EASI scores decreased quickly to a level indicating 'mild disease' (EASI < 7), and remained low in both countries. However, PROMs showed different trajectories with better scores in Japan.

Conclusions: Dupilumab showed significant, comparable and sustained improvement of EASI scores in Japanese and Dutch patients. However, we found striking differences in the effect on PROMs between the countries, with a better outcome in Japanese patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effectiveness of dupilumab in patients with atopic dermatitis: outcome measures over time during dupilumab treatment. All outcome measures have shown clinically relevant improvement with at least one unit of minimal clinically important difference. (a) The EASI score shows a rapid decrease with comparable trajectories in both countries, while Patient‐Reported Outcome Measures (PROMs) [(b) Patient‐Oriented Eczema Measure and (c) Numeric Rating Scale (NRS)‐Pruritus] showed different trajectories with relatively high scores and a clinically relevant, better outcome for PROMs in JP patients. (c) NRS‐Pruritus shows peak pruritus past 24 h (NL) and mean pruritus past 7 days (JP). (d) DLQI score in time during dupilumab treatment. (e) TARC levels after starting dupilumab treatment (in JP patients). Bands show 95% confidence intervals
See this image and copyright information in PMC

Comment in

References

    1. Katoh N, Kataoka Y, Saeki Het al. Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials. Br J Dermatol 2020; 183:39–51. - PMC - PubMed
    1. Brunner PM, Guttman‐Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol 2019; 122:449–55. - PubMed
    1. Kaufman BP, Guttman‐Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups – variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol 2018; 27:340–57. - PubMed
    1. Noda S, Suárez‐Fariñas M, Ungar Bet al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol 2015; 136:1254–64. - PubMed
    1. Osawa R, Konno S, Akiyama Met al. Japanese‐specific filaggrin gene mutations in Japanese patients suffering from atopic eczema and asthma. J Invest Dermatol 2010; 130:2834–6. - PubMed

Publication types

Substances